Gilead Sciences | GILD - Прибыль до налогообложения

Биржевая цена
130.84
Изменение за день
2.00 1.55%
Ежемесячно
-6.12%
Ежегодный
26.72%
Q2 прогноз
127.61




Прибыль до налогообложения Изменить Дата
AbbVie USD 5.57B 2.9B 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
ALKERMES USD 100.74M 4.1M 2025-09
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Glaxosmithkline GBP 2.46B 569M 2025-09
Incyte USD 389.94M 92.37M 2025-12
J&J USD 7.82B 2.86B 2026-03
Merck USD 3.42B 3.32B 2025-12
Moderna USD -187M 631M 2025-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 5.5B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
United Therapeutics USD 444M 6M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09